Skip to content
Nonprofiteer
← QUANTUM LEAP HEALTH CARECOLLABORATIVE

Form 990 for tax year 2024

Filed by QUANTUM LEAP HEALTH CARECOLLABORATIVE.

Totals

Total revenue
$45,532,346
Total expenses
$62,568,780
Contributions and grants received
$878,580
Grants paid
$0
Program service revenue
$42,490,974
Investment income
$2,241,408
Other revenue
-$78,616
Total assets, end of year
$40,228,761
Total liabilities, end of year
$28,835,901
Net assets or fund balances, end of year
$11,392,860
Program services expenses (Part IX)
$55,329,291
Management and general expenses
$6,677,435
Fundraising expenses
$562,054
Program service expenses (Part III)
$55,329,291

Program services were 88.4% of total expenses calculated — Part IX's program-services column over total expenses, both as filed.

Line items

Every line the filer filed in Parts VIII, IX and X, as filed and in filed order. Blank columns are left out, and the lines are not forced to add up to the totals above.

Revenue

Part VIII, the statement of revenue.

  • 1f · All other contributions, gifts and grants

    $878,580

  • 1g · Noncash contributions included above

    $395,956

  • 2a · Program service revenue: CLINICAL TRIAL CONTRAC

    total $42,345,174 · related or exempt $42,345,174

  • 2b · Program service revenue: CONSULTING AND RESEARC

    total $145,800 · related or exempt $145,800

  • 3 · Investment income

    total $1,432,868 · excluded $1,432,868

  • 7a · Gross sales of assets other than inventory

    securities $78,733,129

  • 7b · Less cost or other basis and sales expenses

    securities $77,924,589

  • 7c · Gain or loss

    securities $808,540

  • 7d · Net gain or loss

    total $808,540 · excluded $808,540

  • 8a · Fundraising events: gross income

    $215,672

  • 8b · Fundraising events: direct expenses

    $294,288

  • 8c · Net income from fundraising events

    total -$78,616 · excluded -$78,616

Functional expenses

Part IX, the statement of functional expenses.

  • 5 · Compensation of officers, directors and key employees

    total $3,105,478 · program services $1,850,296 · management and general $1,255,182

  • 7 · Other salaries and wages

    total $15,158,881 · program services $11,987,556 · management and general $2,819,655 · fundraising $351,670

  • 8 · Pension plan contributions

    total $567,974 · program services $431,075 · management and general $125,864 · fundraising $11,035

  • 9 · Other employee benefits

    total $2,689,049 · program services $2,065,148 · management and general $568,456 · fundraising $55,445

  • 10 · Payroll taxes

    total $1,628,956 · program services $1,236,328 · management and general $360,979 · fundraising $31,649

  • 11b · Fees: legal

    total $76,645 · management and general $76,645

  • 11c · Fees: accounting

    total $223,585 · management and general $223,585

  • 11f · Fees: investment management

    total $22,019 · management and general $22,019

  • 11g · Fees: other

    total $2,523,787 · program services $2,405,958 · management and general $79,148 · fundraising $38,681

  • 13 · Office expenses

    total $135,135 · program services $76,347 · management and general $56,496 · fundraising $2,292

  • 14 · Information technology

    total $3,645,484 · program services $3,071,077 · management and general $517,687 · fundraising $56,720

  • 16 · Occupancy

    total $334,179 · program services $240,424 · management and general $87,372 · fundraising $6,383

  • 17 · Travel

    total $1,396,428 · program services $939,557 · management and general $451,718 · fundraising $5,153

  • 19 · Conferences, conventions and meetings

    total $57 · program services $39 · management and general $18

  • 20 · Interest

    total $12 · program services $6 · management and general $6

  • 22 · Depreciation, depletion and amortization

    total $89,494 · program services $68,311 · management and general $19,361 · fundraising $1,822

  • 23 · Insurance

    total $94,279 · program services $80,010 · management and general $13,065 · fundraising $1,204

  • 24a · Other expenses: RESEARCH SITES

    total $21,213,316 · program services $21,213,316

  • 24b · Other expenses: PROGRAM MANAGEMENT

    total $8,120,140 · program services $8,120,140

  • 24c · Other expenses: RESEARCH

    total $1,543,882 · program services $1,543,703 · management and general $179

Balance sheet

Part X, book values.

  • 1 · Cash, non-interest-bearing

    beginning of year $249,898 · end of year $2,817,987

  • 2 · Savings and temporary cash investments

    beginning of year $5,385,955 · end of year $206,247

  • 3 · Pledges and grants receivable

    beginning of year $279,603 · end of year $75,000

  • 4 · Accounts receivable

    beginning of year $8,639,920 · end of year $16,199,006

  • 9 · Prepaid expenses and deferred charges

    beginning of year $725,047 · end of year $683,729

  • 10a · Land, buildings and equipment: cost or other basis

    $328,967

  • 10b · Land, buildings and equipment: accumulated depreciation

    $248,388

  • 10c · Land, buildings and equipment, net

    beginning of year $113,294 · end of year $80,579

  • 11 · Investments: publicly traded securities

    beginning of year $42,672,001 · end of year $20,130,413

  • 15 · Other assets

    beginning of year $136,242 · end of year $35,800

  • 17 · Accounts payable and accrued expenses

    beginning of year $12,880,683 · end of year $16,757,091

  • 19 · Deferred revenue

    beginning of year $15,030,847 · end of year $10,615,617

  • 25 · Other liabilities

    beginning of year $1,463,193 · end of year $1,463,193

  • 27 · Net assets without donor restrictions

    beginning of year $28,638,301 · end of year $11,077,690

  • 28 · Net assets with donor restrictions

    beginning of year $188,936 · end of year $315,170

Mission and programs · 2024

Mission

THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.

Activities or mission (Part I)

THE MISSION OF QUANTUM LEAP HEALTHCARE COLLARBORATIVE IS TO PROVIDE (CONTINUED ON SCHEDULE O)MANAGEMENT AND FINANCIAL SUPPORT TO HEALTHCARE RESEARCH ORGANIZATIONS, PARTICULARLY INVOLVING BREAST CANCER RESEARCH AND TREATMENT.

  • ISPY 2.2 - I-SPY 2.2 USES A 'SEQUENTIAL MULTIPLE ASSIGNMENT RANDOMIZED TRIAL' (SMART) DESIGN - THAT IS BOTH SMART AND ADAPTIVE. THE TRIAL CONSISTS OF UP TO THREE BLOCKS OF TREATMENT. THE FIRST, BLOCK A, INCLUDES NOVEL TARGETED THERAPIES, WITHOUT STANDARD CHEMOTHERAPY. IF A PATIENT ACHIEVES A COMPLETE RESPONSE AFTER BLOCK A, THEY CAN AVOID TOXIC CHEMOTHERAPY AND GO DIRECTLY TO SURGERY. IF THEY HAVE RESIDUAL CANCER, OR THE TREATMENT IS FOUND TO HAVE LITTLE EFFECT HALFWAY THROUGH THE COURSE OF TREATMENT, THEY ARE RECOMMENDED TO PROCEED TO TREATMENT IN BLOCK B. IN BLOCK B, PATIENTS ARE ASSIGNED A TREATMENT REGIMEN MOST LIKELY TO WORK FOR THEIR SUBTYPE, OFTEN COMBINED WITH CHEMOTHERAPY SINCE THE RISK OF TOXICITY IS MORE ACCEPTABLE IN PATIENTS WITH MORE RESISTANT CANCER. (CONTINUED ON SCHEDULE O)IF BLOCK B TREATMENT IS EFFECTIVE, THE PATIENT CAN SKIP ADDITIONAL CHEMOTHERAPY AND GO TO SURGERY. ONLY IF THEY STILL HAVE TUMOR LEFT AFTER BLOCK B, WILL THE PATIENTT GET RESCUE THERAPY WITH DOXORUBICIN AND CYCLOPHOSPHAMIDE A CHEMOTHERAPY REGIMEN THAT HAS BEEN AROUND FOR DECADES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 36.9%

    Expenses $31,082,090 · Revenue $28,146,883

  • DCIS - THE RE-EVALUATING CONDITIONS FOR ACTIVE SURVEILLANCE SUITABILITY AS TREATMENT: DUCTAL CARCINOMA IN SITU (RECAST DCIS) PLATFORM TRIAL IS A LANDMARK PHASE 2 TRIAL THAT IS CHANGING THE LENS THROUGH WHICH WE TREAT DCIS. THE STUDY IS AIMED AT PREVENTING THE PROGRESSION OF DCIS TO BREAST CANCER AND IS EVALUATING THREE INVESTIGATIONAL ENDOCRINE THERAPY ARMS.WITH THE OBJECTIVE TO AVOID OVER-TREATMENT OF LOW-RISK DCIS PATIENTS, THIS NEW TRIAL OFFERS DCIS PATIENTS ENDOCRINE THERAPY WITH THE INTENT TO IDENTIFY PATIENTS WHO ARE RESPONSIVE TO NON-INVASIVE TREATMENT AND HAVE THE OPTION TO OMIT SURGERY AND BE MONITORED VIA LONG-TERM ACTIVE SURVEILLANCE. (CONTINUED ON SCHEDULE O)A KEY ELEMENT IN REDUCING OVER TREATMENT OF DCIS IS IDENTIFYING BIOMARKERS THAT REFLECT THE RISK OF PROGRESSION SO THAT THOSE WITH LOW-RISK LESIONS ARE SPARED SURGERY. RECAST DCIS FEATURES THE ASSESSMENT OF MRI IMAGING AND MOLECULAR-BASED BIOMARKER ANALYSES IN ADDITION TO EVALUATING NEW INVESTIGATIONAL AGENTS IN THIS SETTING. IF PATIENTS AND THEIR PHYSICIANS AGREE, THEY MAY BE ABLE TO STAY ON ENDOCRINE THERAPY FOR UP TO THREE YEARS. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.2%

    Expenses $2,337,901 · Revenue $3,517,864

  • PHASE1B - PRE I-SPY IS AN OPEN-LABEL PHASE 1B PLATFORM STUDY DESIGNED TO EVALUATE SINGLE AGENTS OR COMBINATIONS IN A METASTATIC TREATMENT SETTING THAT MAY BE RELEVANT FOR BREAST CANCER PATIENTS WITH THE OVERALL GOAL OF MOVING PROMISING DRUG REGIMENS INTO THE I-SPY 2.2 TRIAL AND/OR OTHER ONCOLOGY-BASED TRIALS IN A TIMELY MANNER. THE PRIMARY OBJECTIVES OF THIS PLATFORM TRIAL ARE TO DETERMINE THE SAFETY AND TOLERABILITY OF NEW AGENTS/REGIMES IN PATIENTS WITH CERTAIN ADVANCED SOLID TUMORS AND BREAST CANCER WHILE OBTAINING PRELIMINARY EFFICACY DATA OF THE NEW AGENTS/REGIMES. THE STUDY WAS DEVELOPED TO HELP INVESTIGATORS AND INDUSTRY PARTNERS MEET THE SAFETY QUALIFICATIONS NECESSARY FOR PARTICIPATION IN I-SPY 2.2 (CONTINUED ON SCHEDULE O) TRIAL AND/OR OTHER PHASE II/III STUDIES. AVERAGE OVERHEAD BOOKED TO PROGRAM IN FY2024 = 7.00%

    Expenses $271,185 · Revenue $1,877,278

  • OTHER PROGRAMS INCLUDE BREAST CANCER TRIALS (BCT) MATCH, COVID-19 TRIALS, I-SPY 2.0, ENDOCRINCE OPTIMIZATION PROJECT (EOP) TRIALS, AND ONE SOURCE AI.

    Expenses $21,638,115 · Revenue $8,948,949

As filed on the 2024 return. The filer continues this part on Schedule O, which is not shown here.

Listed in Part VII

  • Dave Mandelkern Ms

    CHAIRMAN

    Total calculated
    $120,000
    From this org
    $120,000
    From related orgs
    $0
    Other
    $0
    Hours/week
    8

  • Laura Esserman

    DIRECTOR, CO-FOUNDER

    Total calculated
    $0
    Hours/week
    0.5

  • Anna Barker PhD

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Lucas De Breed PhD MBA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Susan Foley CFA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Michele Markus

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Jeffrey Pfeffer

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Robyn Lawrie Rutledge MBA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Gregory C Simon

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Mark Simon MBA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • N Marcus Thygeson MD MPH

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • Lambert Van Der Walde MBA

    DIRECTOR

    Total calculated
    $0
    Hours/week
    0.5

  • James Palazzolo

    CEO

    Total calculated
    $780,650
    From this org
    $705,144
    From related orgs
    $0
    Other
    $75,506
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $600,144
    Bonus
    $105,000
    Other
    $0
    Deferred
    $29,250
    Nontaxable benefits
    $46,256
    Filer's total
    $780,650

  • Kathryn Watson-Feiner

    VICE PRESIDENT OF FINANCE

    Total calculated
    $522,044
    From this org
    $471,944
    From related orgs
    $0
    Other
    $50,100
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $471,944
    Bonus
    $0
    Other
    $0
    Deferred
    $3,833
    Nontaxable benefits
    $46,267
    Filer's total
    $522,044

  • Imogene Mdunn

    VICE PRES. STATISTICS (THRU 11/24)

    Total calculated
    $519,823
    From this org
    $489,716
    From related orgs
    $0
    Other
    $30,107
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $308,260
    Bonus
    $0
    Other
    $181,456
    Deferred
    $0
    Nontaxable benefits
    $30,107
    Filer's total
    $519,823

  • Radhika Sivaramakrishna

    SR. VP, CLINICAL OPS & COMPLIANCE

    Total calculated
    $401,580
    From this org
    $344,211
    From related orgs
    $0
    Other
    $57,369
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $344,211
    Bonus
    $0
    Other
    $0
    Deferred
    $11,113
    Nontaxable benefits
    $46,256
    Filer's total
    $401,580

  • Pinaki Chakraborty

    VP QUALITY ASSURANCE

    Total calculated
    $333,180
    From this org
    $276,863
    From related orgs
    $0
    Other
    $56,317
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $276,863
    Bonus
    $0
    Other
    $0
    Deferred
    $12,660
    Nontaxable benefits
    $43,657
    Filer's total
    $333,180

  • Adam Asare

    CHIEF DATA OFFICER

    Total calculated
    $285,753
    From this org
    $270,697
    From related orgs
    $0
    Other
    $15,056
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $270,697
    Bonus
    $0
    Other
    $0
    Deferred
    $12,092
    Nontaxable benefits
    $2,964
    Filer's total
    $285,753

  • Annuska Glas

    VP BIOMARKER & INNOVATION

    Total calculated
    $251,582
    From this org
    $222,484
    From related orgs
    $0
    Other
    $29,098
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $222,484
    Bonus
    $0
    Other
    $0
    Deferred
    $0
    Nontaxable benefits
    $29,098
    Filer's total
    $251,582

  • Philip Beineke

    DIRECTOR OF BIOMETRICS, ONCOLOGY

    Total calculated
    $380,002
    From this org
    $317,177
    From related orgs
    $0
    Other
    $62,825
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $317,177
    Bonus
    $0
    Other
    $0
    Deferred
    $15,191
    Nontaxable benefits
    $47,634
    Filer's total
    $380,002

  • Ami Okada

    DIRECTOR OF I-SPY COVID TRIAL

    Total calculated
    $342,067
    From this org
    $292,216
    From related orgs
    $0
    Other
    $49,851
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $292,216
    Bonus
    $0
    Other
    $0
    Deferred
    $7,716
    Nontaxable benefits
    $42,135
    Filer's total
    $342,067

  • Karyn Digiorgio

    CHIEF COLLABORATION OFFICER

    Total calculated
    $327,478
    From this org
    $280,507
    From related orgs
    $0
    Other
    $46,971
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $280,507
    Bonus
    $0
    Other
    $0
    Deferred
    $13,351
    Nontaxable benefits
    $33,620
    Filer's total
    $327,478

  • Paul Henderson

    SR. DIRECTOR OF COLLABORATIONS

    Total calculated
    $307,672
    From this org
    $248,859
    From related orgs
    $0
    Other
    $58,813
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $248,859
    Bonus
    $0
    Other
    $0
    Deferred
    $11,266
    Nontaxable benefits
    $47,547
    Filer's total
    $307,672

  • Sara Horton

    EXECUTIVE DIRECTOR, DIVERSITY

    Total calculated
    $274,109
    From this org
    $241,574
    From related orgs
    $0
    Other
    $32,535
    Hours/week
    40

    Schedule J breakdown matched by us

    Base
    $241,574
    Bonus
    $0
    Other
    $0
    Deferred
    $4,629
    Nontaxable benefits
    $27,906
    Filer's total
    $274,109

Compensation is as filed in Part VII: reportable pay from this organization and from related organizations, other compensation, and hours per week. The total, marked calculated, is our sum of the three dollar columns, with a blank column counted as $0; the form itself has no total. On a Form 990-EZ the columns are Part IV's instead, and on a Form 990-PF Part VIII's — compensation, contributions to benefit plans, and expense account — and the total sums those. A Schedule J breakdown is as filed: base pay, bonus, other, deferred compensation and nontaxable benefits from this organization, with any from related organizations beside each, and the filer's own total. It is shown with the Part VII listing of the same name on the same return. The form gives no key between the two, so that pairing is ours, and is marked matched by us.

Schedule J

Answered yes

  • 3 · Compensation committee
  • 3 · Form 990 of other organizations
  • 3 · Written employment contract
  • 3 · Compensation survey or study
  • 3 · Approval by the board or compensation committee
  • 4a · Severance or change-of-control payment
  • 7 · Other non-fixed payments

Answered no

  • 4b · Supplemental nonqualified retirement plan
  • 4c · Equity-based compensation arrangement
  • 5a · Pay contingent on this organization's revenues
  • 5b · Pay contingent on a related organization's revenues
  • 6a · Pay contingent on this organization's net earnings
  • 6b · Pay contingent on a related organization's net earnings
  • 8 · Paid under the initial-contract exception

The filer's explanations (Part III)

PART I, LINE 4A
IMOGENE M. DUNN, VICE PRESIDENT STATISTICS, RECEIVED A SEVERANCE PAYMENT OF $181,456.
PART I, LINE 7
DISCRETIONARY BONUSES ARE APPROVED BY THE BOARD OF DIRECTORS.

Part I's answers as filed. A line not listed was left unanswered; on lines 1a and 3 that means the box was not checked.

Grants on this return

No itemized grants to organizations on this return.

Provenance

Return type
form_990
Tax year
2024
Filed
17 November 2025
IRS schema version
2024v5.2
Source object
202543219349320879

Check it against the return as filed: the GivingTuesday Data Lake hosts a public copy of the original XML.

The source document this was parsed from is served over the API, which is where bulk and document access live.